Literature DB >> 7706731

Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma.

A Choudhary1, F Davodeau, A Moreau, M A Peyrat, M Bonneville, F Jotereau.   

Abstract

We show here that tumor infiltrating lymphocytes (TIL) derived from three renal carcinoma (RC) tumors, which developed in the same patient over a 3-yr period, were systematically enriched in gamma delta + T cells (27-74%) after short term in vitro culture. Analysis of the repertoire of gamma delta + TIL and PBL from this patient, revealed the predominant expression of structurally diverse V delta 1 gamma delta TCR by TIL from the three tumors, contrasting with the classically dominant use of V delta 2 TCR by PBL. Functional analysis further showed that, independently of the V gamma genes expressed, all the V delta 1+ TIL clones exhibited a lytic activity apparently restricted to RC lines, while V gamma 9+V delta 2+ clones (either PBL- or TIL-derived) had a broad killing activity. Surprisingly most V delta 1+ CTL clones lysed several allogeneic, but not the autologous, RC lines. Only one V gamma 3+V delta 1+ TIL clone, identified by its specific variable TCR gene sequence, consistently killed autologous tumor cells, apparently via TCR-mediated MHC-unrestricted recognition. This clone also lysed two allogeneic RC lines out of four tested but did not kill 30 non-RC lines, except for one breast carcinoma line. Significantly, this clone was found in recurrent fashion in all three tumors analyzed, including a metastasis. The high frequency of V delta 1 expressing RC-reactive gamma delta cells among TIL from this patient suggests that this gamma delta subset was selectively trapped and/or preferentially induced to proliferate in the autologous tumors. The recurrence of a single V gamma 3+V delta 1+ gamma delta clone, reacting with autologous tumor cells, inside three tumors of different localizations additionally suggests that, for this clone, intratumor selection and/or proliferation was due to TCR-mediated recognition of a non-MHC-restricted RC-specific Ag.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7706731

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

Review 1.  Tissue distribution, antigen specificity and effector functions of gamma delta T cells in human diseases.

Authors:  G De Libero
Journal:  Springer Semin Immunopathol       Date:  2000

2.  Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme.

Authors:  Nichole L Bryant; G Yancey Gillespie; Richard D Lopez; James M Markert; Gretchen A Cloud; Catherine P Langford; Hilal Arnouk; Yun Su; Hilary L Haines; Catalina Suarez-Cuervo; Lawrence S Lamb
Journal:  J Neurooncol       Date:  2010-06-10       Impact factor: 4.130

3.  γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.

Authors:  Mounia Sabrina Braza; Bernard Klein; Geneviève Fiol; Jean-François Rossi
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

Review 4.  CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.

Authors:  G Elizabeth Pluhar; Christopher A Pennell; Michael R Olin
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

Review 5.  Gammadelta T cells as immune effectors against high-grade gliomas.

Authors:  Lawrence S Lamb
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

6.  NK cells and gammadelta T cells mediate resistance to polyomavirus-induced tumors.

Authors:  Rabinarayan Mishra; Alex T Chen; Raymond M Welsh; Eva Szomolanyi-Tsuda
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

7.  TCRγ4δ1-engineered αβT cells exhibit effective antitumor activity.

Authors:  Kangxia He; Hongqin You; Yuxia Li; Lianxian Cui; Jianmin Zhang; Wei He
Journal:  Mol Med       Date:  2016-07-26       Impact factor: 6.354

8.  Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma.

Authors:  Brant A Inman; Xavier Frigola; Kimberley J Harris; Susan M Kuntz; Christine M Lohse; Bradley C Leibovich; Eugene D Kwon
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

9.  Phenotypic and functional alterations of Vgamma2Vdelta2 T cell subsets in patients with active nasopharyngeal carcinoma.

Authors:  Kia Joo Puan; John Seng Hooi Low; Terence Wee Kiat Tan; Joseph Tien Seng Wee; Eng Huat Tan; Kam Weng Fong; Eu Tiong Chua; Chenggang Jin; José-Luis Giner; Craig T Morita; Christopher Hood Keng Goh; Kam M Hui
Journal:  Cancer Immunol Immunother       Date:  2008-11-30       Impact factor: 6.968

Review 10.  Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Authors:  Christiane Geiger; Elfriede Nössner; Bernhard Frankenberger; Christine S Falk; Heike Pohla; Dolores J Schendel
Journal:  J Mol Med (Berl)       Date:  2009-03-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.